EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of TP53 mutational status and survival in anaplastic thyroid cancer treated with dabrafenib plus trametinib

Ricardo Rodrigues iD, Tiago Nunes da Silva iD, Ana Saramago iD, Daniela Cavaco, Saudade André, Raquel Dias, Miguel Rito iD, Valeriano Leite iD, Branca Maria Cavaco iD

European Thyroid Journal · 2026

DOI: 10.1530/etj-26-0135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, 2026. Verfasst von Ricardo Rodrigues und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) , Lisboa, Portugal. Hauptthemen laut MEDLINE: Pyridones, Oximes, Imidazoles, Pyrimidinones. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Anaplastic thyroid cancer (ATC) is an extremely aggressive tumour, with a high mortality rate. Dabrafenib plus trametinib (DT) has significantly impacted the survival of patients with BRAF p.V600E ATC, with noticeable variations in survival between patients. TP53 is frequently mutated in ATC, but its impact on DT response is still unclear. We aimed to investigate the association between TP53 mutational status and clinical outcomes in ATC patients treated with DT.

Methods

Patients with BRAF-positive ATC (n = 25) treated with DT between 2018 and 2026 were included. Response was assessed by RECIST 1.1. TP53 association with clinicopathological features was evaluated. Four BRAF-mutant cell lines were used: two TP53-mutant (T235 and T238) and two TP53 wild-type (OCUT1 and IHH4).

Results

TP53 mutations, detected in ATC from 10 patients, were associated with a significantly lower overall survival (6.5 vs 21 months; P < 0.01) and a trend towards shorter progression-free survival (7 vs 19 months; P = 0.09) and duration of response (5.5 vs 9 months; P = 0.09). No significant associations were found between TP53 mutations and sex, primary tumour size, N and M stage, or PI3K pathway alterations. Complementary in vitro experiments across four BRAF p.V600E cell lines provided mechanistic support for these clinical observations, demonstrating that TP53-mutant cells consistently exhibited reduced sensitivity to combined DT therapy.

Conclusion

This study suggested that TP53 mutations represent a prognostic factor, associated with worse survival in patients with BRAF p.V600E ATC undergoing DT treatment, highlighting the potential clinical value of incorporating TP53 profiling into patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesOximesImidazolesPyrimidinonesThyroid Carcinoma, AnaplasticTumor Suppressor Protein p53MutationAntineoplastic Combined Chemotherapy ProtocolsThyroid NeoplasmsHumansFemaleMaleAgedProto-Oncogene Proteins B-rafMiddle AgedAged, 80 and overCell Line, Tumor

Stichwörter der Autor:innen

TP53anaplastic thyroid cancerdabrafenibmolecular profilingtrametinib

Substanzen

PyridonesOximesImidazolesPyrimidinonestrametinibdabrafenibTumor Suppressor Protein p53Proto-Oncogene Proteins B-rafTP53 protein, humanBRAF protein, human

Autor:innen und Institutionen

  • Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) , Lisboa, Portugal.
  • NOVA Medical School|Faculdade de Ciências Médicas da Universidade NOVA de Lisboa , Lisboa, Portugal.
  • Serviço de Endocrinologia, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) , Lisboa, Portugal.
  • Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) , Lisboa, Portugal.
  • Serviço de Radiologia, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) , Lisboa, Portugal.
  • Instituto de Anatomia Patológica, Faculdade de Medicina, Universidade de Lisboa , Lisboa, Portugal.

ORCID-Profile: Ricardo Rodrigues, Tiago Nunes da Silva, Ana Saramago, Miguel Rito, Valeriano Leite, Branca Maria Cavaco

Zitieren

APA

Rodrigues, R., da Silva, T. N., Saramago, A., Cavaco, D., André, S., Dias, R., Rito, M., Leite, V., & Cavaco, B. M. (2026). Association of TP53 mutational status and survival in anaplastic thyroid cancer treated with dabrafenib plus trametinib. European Thyroid Journal. https://doi.org/10.1530/etj-26-0135

Vancouver

Rodrigues R, da Silva TN, Saramago A, Cavaco D, André S, Dias R, et al. Association of TP53 mutational status and survival in anaplastic thyroid cancer treated with dabrafenib plus trametinib. European Thyroid Journal. 2026. doi:10.1530/etj-26-0135

BibTeX
@article{Rodrigues2026,
  author = {Rodrigues, Ricardo and da Silva, Tiago Nunes and Saramago, Ana and Cavaco, Daniela and André, Saudade and Dias, Raquel and Rito, Miguel and Leite, Valeriano and Cavaco, Branca Maria},
  title = {Association of TP53 mutational status and survival in anaplastic thyroid cancer treated with dabrafenib plus trametinib},
  journal = {European Thyroid Journal},
  year = {2026},
  doi = {10.1530/etj-26-0135}
}
Kostenlos starten →